Back to News
Market Impact: 0.3
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma
Source: Nasdaq
Healthcare & Biotech
AbbVie and Genmab reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial, evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. The report provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ABBV0.70
GMAB0.70
More News
- European stocks rise 1% as French debt calms and ECB’s Lane tempers hawks
- Stock Movers: Genmab, Sabadell, Vend (Podcast)
- Genmab: Epkinly Shines In Phase 3 DLBCL Trial
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio